Antibiotics specialist Antabio SAS has raised €25m in a Series B financing round with subscriptions from the AMR Action Fund, the EIC Fund and from existing investors.
https://european-biotechnology.com/wp-content/uploads/2024/04/investment__c__Nature_Design.jpeg8531280Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-12-12 13:11:112024-07-09 13:06:33Antabio SAS raises €25 m in Series B financing
https://european-biotechnology.com/wp-content/uploads/2024/04/VTT_coffee.png10341574Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-12-12 13:00:182024-07-09 13:05:35Production process for cell-based coffee published
This scrappy young city in the heart of Europe is rapidly becoming a magnet for successful start-ups and companies looking for plenty of room to grow, as well as a culture of cooperation and trust.
At the EU Council (10-11 December), agriculture ministers did not reach the qualified majority required to adopt the adapted version of the EU Commission’s draft regulation on new genomic techniques.
Sorbonne University spin-out Carthera SA has closed its Series B financing round with an additional investment of €4.5m at €42m to launch clinical trials.
https://european-biotechnology.com/wp-content/uploads/2024/04/Carthera-Sonocloud-9.png487650Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-12-11 15:22:052024-07-09 13:03:14Cathera SA closes Series B round at €42m
On the occasion of SynbiTECH in London, British Science, Research and Innovation Minister, Andrew Griffith, unveiled a £2bn strategic 10-year plan to foster engineering biology.
Pfizer and Valneva announced the completion of enrolment in Phase 3 VALOR trial for Lyme borreliosis vaccine candidate VLA15. More then 9,000 participants were enrolled.
Eligo Bioscience secures $30m in series B funding, advancing its innovative gene-editing solutions targeting diseases linked to bacterial genes within the human microbiome.
https://european-biotechnology.com/wp-content/uploads/2024/04/RS1684_AdobeStock_39048791-scaled.jpeg17072560Margarita Milidakis/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMargarita Milidakis2023-12-05 11:13:082024-07-09 12:58:33$30m for genetic medicine advancements
Antabio SAS raises €25 m in Series B financing
Latest NewsAntibiotics specialist Antabio SAS has raised €25m in a Series B financing round with subscriptions from the AMR Action Fund, the EIC Fund and from existing investors.
Production process for cell-based coffee published
Latest NewsScientists led by Heiko Rischer from the Finnish research centre VTT have published the proof of concept for cell-based coffee production.
Leipzig: fast-growing life science ecosystem
Sponsored PublicationsThis scrappy young city in the heart of Europe is rapidly becoming a magnet for successful start-ups and companies looking for plenty of room to grow, as well as a culture of cooperation and trust.
Germany blocks deregulation of NGT breeds
Latest NewsAt the EU Council (10-11 December), agriculture ministers did not reach the qualified majority required to adopt the adapted version of the EU Commission’s draft regulation on new genomic techniques.
Cathera SA closes Series B round at €42m
Latest NewsSorbonne University spin-out Carthera SA has closed its Series B financing round with an additional investment of €4.5m at €42m to launch clinical trials.
UK publishes £2bn vision for engineering biology
Latest NewsOn the occasion of SynbiTECH in London, British Science, Research and Innovation Minister, Andrew Griffith, unveiled a £2bn strategic 10-year plan to foster engineering biology.
Valnevas Lyme vaccine trial completes recruitment
Latest NewsPfizer and Valneva announced the completion of enrolment in Phase 3 VALOR trial for Lyme borreliosis vaccine candidate VLA15. More then 9,000 participants were enrolled.
Unveiling prostate cancer’s Achilles’ heel
Latest NewsResearchers uncover a potential strategy to target and inhibit the androgen receptor in aggressive prostate cancer by exploiting protein droplets.
$30m for genetic medicine advancements
Latest NewsEligo Bioscience secures $30m in series B funding, advancing its innovative gene-editing solutions targeting diseases linked to bacterial genes within the human microbiome.
Takeover in ADC space: Abbvie snags ImmunoGen
Latest NewsAbbVie buys ImmunoGen in US$10 billion deal, gains access to ADC for ovarian cancer. The ADC space gets hotter and hotter.